Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of Weekly Paclitaxel With or Without KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Verwacht)
Inschrijving
Fase
Fase
- Fase 2
Contacten en locaties
Studiecontact
Studiecontact
- Naam: yi ba, PhD
- Telefoonnummer: 13752157916
- E-mail: bayi@timuch.com
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- 1.Prior to any detailed procedures of this study, subjects are able to understand, voluntarily participate in and sign the informed consent approved by the ethics committee.
- 2.Age ≥ 18 years.
- 3.Histologically confirmed, unresectable, locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma .
- 4.Have at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.
- 5.Have experienced documented objective radiographic or symptomatic disease progression during first-line therapy, or within 4 months after the last dose of first-line therapy with any platinum or/and fluoropyrimidine doublet for unresectable or metastatic disease.Second line chemotherapy is suitable for paclitaxel.
- 6.Laboratory test values must meet the following criteria. ANC ≥1.5×109/L, platelets ≥ 100×109/L, hemoglobin≥9g/dL. Blood creatinine ≤ 1.5 ×ULN or creatinine clearance ≥ 50 mL/min/m2. Total bilirubin ≤ 1.5× ULN(≤ 3 x ULN if Gilbert disease), AST and ALT ≤ 2.5× ULN (≤ 5×ULN if hepatic metastasis).
INR ≤ 1.5× ULN, APTT ≤ 1.5× ULN. Dipstick proteinuria <2+ or 24 hour proteinuria <1g .
- 7.Good performance status Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 to 1.
- 8.Life expectancy of ≥ 3 months.
Exclusion Criteria:
- 1.Histologically confirmed squamous cell carcinoma or undifferentiated gastric cancer.
- 2.Patients with disease progression within 6 months after previous adjuvant or neoadjuvant chemotherapy with paclitaxel, or patients with recurrent or metastatic gastric adenocarcinoma or GEJ adenocarcinoma treated with paclitaxel.
- 3. GI perforation and/or fistulae in the 6 months preceding randomization.
- 4.Deep-vein thrombosis, pulmonary embolism (PE), or any other episode of Uncontrolled thromboembolism in the 6 months preceding randomization.
- 5.Any arterial thromboembolic event (such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack)
- 6.Uncontrolled hypertension (≥150/100 mm Hg ) despite properly observed antihypertensive therapy.
- 7.Known brain metastasis.
- 8.Known allergy to paclitaxel or KH903.
- 9.Serious concurrent infection or medical illness.
- 10.Active hepatitis B virus or Active hepatitis C virus (HCV) infection at screening.
- 11.Any condition which results in an undue risk for the patient during the trial participation according to the investigator.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: KH903 + Paclitaxel
IV KH903 4 mg/kg IV paclitaxel 80 mg/m²
|
KH903 4 mg/kg will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle; Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
|
|
Actieve vergelijker: Placebo + Paclitaxel
IV Placebo IV paclitaxel 80 mg/m²
|
Placebo will be administered intravenously on D1 D8 D15and D22 in a 28-day cycle; Paclitaxel 80 mg/m² will be administered intravenously on D1, D8 and D15 in a 28-day cycle
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free survival(PFS)
Tijdsspanne: Time from date of randomization until the date of first documented Progression or date of death from any cause, whichever came frist,assessed up to18 months
|
Date of randomization until the date of first documented Progression or date of death from any cause, whichever came first
|
Time from date of randomization until the date of first documented Progression or date of death from any cause, whichever came frist,assessed up to18 months
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate (ORR)
Tijdsspanne: Time from date of randomization until the date of first documented CR or PR,assessed up to18 months
|
Percentage of Participants with a Best Overall Response (BOR) of Partial Response (PR) or Complete Response (CR)
|
Time from date of randomization until the date of first documented CR or PR,assessed up to18 months
|
|
Duration of Response (DOR)
Tijdsspanne: Time from first documented evidence of CR or PR until the date of first documented progression ,assessed up to18 months
|
is defined as the time from first documented evidence of CR or PR until the date of first documented progression as assessed by RECIST 1.1 or death; assessed up to18 months
|
Time from first documented evidence of CR or PR until the date of first documented progression ,assessed up to18 months
|
|
Disease Control Rate (DCR)
Tijdsspanne: Time from date of randomization until the date of first documented Progression,assessed up to18 months
|
Percentage of Participants who have achieved CR, PR and SD to study treatment;
|
Time from date of randomization until the date of first documented Progression,assessed up to18 months
|
|
AE
Tijdsspanne: AEs(NCI CTCAE 5.0) collected at each cycle,Assessed up to18 months
|
Number of Subjects with treatment-related adverse events (AEs)Defined by all
|
AEs(NCI CTCAE 5.0) collected at each cycle,Assessed up to18 months
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: yi ba, PhD, Tianjin Medical University Cancer Institute and Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Studie start
Primaire voltooiing (Verwacht)
Primaire voltooiing
Studie voltooiing (Verwacht)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per histologisch type
- Neoplasmata
- Carcinoom
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Moleculaire mechanismen van farmacologische werking
- Antineoplastische middelen
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Antineoplastische middelen, fytogeen
- Paclitaxel
- Albumine-gebonden paclitaxel
Andere studie-ID-nummers
Andere studie-ID-nummers
- KH903-40101-CRP
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .